Featured AnalysisThe ICH Q11 Three-Part Justification — What FDA and EMA Require for Starting Material Designation and Where Programs Fall ShortXGene analysis · Aug 22, 2026Read Article →
Latest Warning LetterInside Genzyme’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptWARNING LETTER · Aug 22, 2026Open Regulatory Record →
Featured AnalysisFDA Inspection Front Room Protocol — What to Say and What Not ToXGene analysis · Aug 22, 2026Read Article →
Latest Warning LetterInside Ranbaxy’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptWARNING LETTER · Aug 22, 2026Open Regulatory Record →
CMC AnalysisSalt and Co-Crystal Selection: CMC Documentation of Pharmaceutical Form Decisions in Module 3XGene analysis · Aug 22, 2026Explore CMC Analysis →
FDA 483 SignalInside PharMEDium’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptFDA 483 · Aug 22, 2026Open Regulatory Record →
Featured AnalysisPolymorphism in Drug Substances: The ICH Q6A Decision Tree, Solid-State Characterization, and Process-Induced Form Conversion RiskXGene analysis · Aug 22, 2026Read Article →
Regulatory SignalZhejiang Gaorong Cosmetic Co., Ltd. Added to Import Alert 66-40: The CGMP Pattern Behind the Detention and What Every Quality Director Managing Cross-Category Drug, Biologic, and Supplement Supply Chains Must KnowIMPORT ALERT · Aug 22, 2026Open Regulatory Record →
Featured AnalysisThe ICH Q11 Three-Part Justification — What FDA and EMA Require for Starting Material Designation and Where Programs Fall ShortXGene analysis · Aug 22, 2026Read Article →
Latest Warning LetterInside Genzyme’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptWARNING LETTER · Aug 22, 2026Open Regulatory Record →
Featured AnalysisFDA Inspection Front Room Protocol — What to Say and What Not ToXGene analysis · Aug 22, 2026Read Article →
Latest Warning LetterInside Ranbaxy’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptWARNING LETTER · Aug 22, 2026Open Regulatory Record →
CMC AnalysisSalt and Co-Crystal Selection: CMC Documentation of Pharmaceutical Form Decisions in Module 3XGene analysis · Aug 22, 2026Explore CMC Analysis →
FDA 483 SignalInside PharMEDium’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptFDA 483 · Aug 22, 2026Open Regulatory Record →
Featured AnalysisPolymorphism in Drug Substances: The ICH Q6A Decision Tree, Solid-State Characterization, and Process-Induced Form Conversion RiskXGene analysis · Aug 22, 2026Read Article →
Regulatory SignalZhejiang Gaorong Cosmetic Co., Ltd. Added to Import Alert 66-40: The CGMP Pattern Behind the Detention and What Every Quality Director Managing Cross-Category Drug, Biologic, and Supplement Supply Chains Must KnowIMPORT ALERT · Aug 22, 2026Open Regulatory Record →
CMC / Module 3 XGene CMC Intelligence CMC / Module 3 Module 3 evidence, control strategy, specifications and lifecycle content. Featured analysis Module 3 Deficiency Patterns 3.2.S.2.2 Description of Manufacturing Process 3.2.S.2.4–2.6 Critical Steps, Process Validation, and Manufacturing Process Development: Building the Process Understanding Evidence Package The Ionizable Lipid pKa Principle: Why the Chemistry You Select at Formulation Development Becomes the CQA You Cannot Escape at BLA 3.2.S.3.2 Drug Substance Impurities: Writing the ICH Q3A-Compliant Impurity Profile FDA Will Accept 3.2.S.4 Drug Substance Specifications, Analytical Methods, and Validation: The Complete Testing Package 3.2.S.5 Reference Standards: The Metrological Foundation Your Entire Analytical Package Depends On 3.2.S.7 Drug Substance Stability: Designing the ICH Q1-Compliant Program That Supports a Defensible Retest Period 3.2.P.2 Pharmaceutical Development: Writing the QbD Narrative That Justifies Every Formulation and Manufacturing Decision 3.2.P.3 Drug Product Manufacture: Batch Formula, Process Description, and Validation Evidence That Survives FDA Review 3.2.P.5.1–5.3 Drug Product Specifications 3.2.P.8 Drug Product Stability: Building the Stability Program That Establishes a Defensible Shelf Life Current regulatory intelligence FDA’s Draft Guidance on Leveraging Prior Knowledge for Genome Editing Gene Therapies — The CMC Precedent-Sharing Framework Every GT Program Should Map Before September 1 Request a CMC Evidence Gap Assessment
3.2.S.2.4–2.6 Critical Steps, Process Validation, and Manufacturing Process Development: Building the Process Understanding Evidence Package
The Ionizable Lipid pKa Principle: Why the Chemistry You Select at Formulation Development Becomes the CQA You Cannot Escape at BLA
3.2.S.4 Drug Substance Specifications, Analytical Methods, and Validation: The Complete Testing Package
3.2.S.7 Drug Substance Stability: Designing the ICH Q1-Compliant Program That Supports a Defensible Retest Period
3.2.P.2 Pharmaceutical Development: Writing the QbD Narrative That Justifies Every Formulation and Manufacturing Decision
3.2.P.3 Drug Product Manufacture: Batch Formula, Process Description, and Validation Evidence That Survives FDA Review
3.2.P.8 Drug Product Stability: Building the Stability Program That Establishes a Defensible Shelf Life
FDA’s Draft Guidance on Leveraging Prior Knowledge for Genome Editing Gene Therapies — The CMC Precedent-Sharing Framework Every GT Program Should Map Before September 1
